Cargando…

Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation

The clinical application of doxorubicin (DOX) in cancer chemotherapy is limited by its life-threatening cardiotoxic effects. Chrysophanol (CHR), an anthraquinone compound isolated from the rhizome of Rheum palmatum L., is considered to play a broad role in a variety of biological processes. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jing, Li, Jingyan, Hu, Yuehuai, Guo, Zhen, Sun, Duanping, Wang, Panxia, Guo, Kaiteng, Duan, Dayue Darrel, Gao, Si, Jiang, Jianmin, Wang, Junjian, Liu, Peiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663922/ https://www.ncbi.nlm.nih.gov/pubmed/31384538 http://dx.doi.org/10.1016/j.apsb.2018.10.008

Ejemplares similares

The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy
por: Wang, Luping, et al.
Publicado: (2022)

Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression
por: Wang, Panxia, et al.
Publicado: (2021)

Sorting nexin 3 exacerbates doxorubicin-induced cardiomyopathy via regulation of TFRC-dependent ferroptosis
por: Yu, Wenjing, et al.
Publicado: (2023)

Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression
por: Wang, Panxia, et al.
Publicado: (2020)

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets
por: Krastev, Dragomir B., et al.
Publicado: (2018)

INKing the Cardiotoxicity Out of Doxorubicin
por: Guo, Zhen, et al.
Publicado: (2023)

SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy
por: Li, Zhenzhen, et al.
Publicado: (2019)

Targeting dePARylation for cancer therapy
por: Kassab, Muzaffer Ahmad, et al.
Publicado: (2020)

Chrysophanol Inhibits the Progression of Diabetic Nephropathy via Inactivation of TGF-β Pathway
por: Guo, Chuan, et al.
Publicado: (2020)

Functions of PARylation in DNA Damage Repair Pathways
por: Wei, Huiting, et al.
Publicado: (2016)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

SPINDOC binds PARP1 to facilitate PARylation
por: Yang, Fen, et al.
Publicado: (2021)

NAMPT and PARylation Are Involved in the Pathogenesis of Atopic Dermatitis
por: Arroyo, Ana B., et al.
Publicado: (2023)

Role of acetylation in doxorubicin-induced cardiotoxicity
por: Li, Daisong, et al.
Publicado: (2021)

DePARylation is critical for S phase progression and cell survival
por: Nie, Litong, et al.
Publicado: (2023)

Isorhamnetin Protects against Doxorubicin-Induced Cardiotoxicity In Vivo and In Vitro
por: Sun, Jing, et al.
Publicado: (2013)

Combat Doxorubicin Cardiotoxicity With the Power of Mitochondria Transfer
por: Wang, Dennis D., et al.
Publicado: (2021)

Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
por: Lin, Xiaoxiao, et al.
Publicado: (2023)

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
por: Cheah, Irwin K., et al.
Publicado: (2023)

PARP1-mediated PARylation activity is essential for oligodendroglial differentiation and CNS myelination
por: Wang, Yan, et al.
Publicado: (2021)

Dipyridamole ameliorates doxorubicin-induced cardiotoxicity
por: Alyasiry, Esraa, et al.
Publicado: (2022)

A Double-Edged Sword: The Two Faces of PARylation
por: Kang, Mincheol, et al.
Publicado: (2022)

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
por: Attachaipanich, Tanawat, et al.
Publicado: (2023)

Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice
por: Fan, Rui, et al.
Publicado: (2023)

Melatonin attenuates doxorubicin‐induced cardiotoxicity through preservation of YAP expression
por: Li, Hai‐ru, et al.
Publicado: (2020)

Chrysophanol: A Natural Anthraquinone with Multifaceted Biotherapeutic Potential
por: Prateeksha,, et al.
Publicado: (2019)

Transcriptomic analysis reveals distinct resistant response by physcion and chrysophanol against cucumber powdery mildew
por: Li, Yanping, et al.
Publicado: (2016)

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers
por: Kamaletdinova, Tatiana, et al.
Publicado: (2019)

Cinnamaldehyde alleviates doxorubicin-induced cardiotoxicity by decreasing oxidative stress and ferroptosis in cardiomyocytes
por: Mao, Meijiao, et al.
Publicado: (2023)

Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity
por: Cappetta, Donato, et al.
Publicado: (2017)

PARylation During Transcription: Insights into the Fine-Tuning Mechanism and Regulation
por: Páhi, Zoltán G., et al.
Publicado: (2020)

Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2
por: Wang(a), Jie, et al.
Publicado: (2022)

Low dose radiation prevents doxorubicin-induced cardiotoxicity
por: Jiang, Xin, et al.
Publicado: (2017)

Morphine Enhances Doxorubicin-Induced Cardiotoxicity in the Rat
por: Hole, Lisa Drange, et al.
Publicado: (2014)

The true colors of autophagy in doxorubicin-induced cardiotoxicity
por: Xiao, Bin, et al.
Publicado: (2019)

UVRAG Deficiency Exacerbates Doxorubicin-Induced Cardiotoxicity
por: An, Lin, et al.
Publicado: (2017)

Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
por: Koleini, Navid, et al.
Publicado: (2017)

Telomerase therapy attenuates cardiotoxic effects of doxorubicin
por: Chatterjee, Shambhabi, et al.
Publicado: (2021)

Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity
por: Wu, Bin Bin, et al.
Publicado: (2022)

Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
por: Özgür Barış, Veysel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u403dju3i7jha126ugqmu0dg51